ACOG Share Price Performance
CA$8.16
-6.59 (-44.68%)
Price CA$8.16
Share PriceCA$8.16
ACOG Community Narratives
There are no narratives available yet.
Recent ACOG News & Updates
No updates
Alpha Cognition Inc. Key Details
Last Reported Earnings
Sep 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.92
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -75.8%
Alpha Cognition Inc. Competitors
About ACOG
- Founded
- 2000
- Employees
- n/a
- CEO
- WebsiteView website
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Canadian Market Performance
- 7 Days: 0.4%
- 3 Months: 7.1%
- 1 Year: 21.0%
- Year to Date: 9.9%
The Materials sector gained 6.0% while the market remained flat over the last week. As for the longer term, the market has risen 23% in the past 12 months. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading